Weekly exposure to deep red light in the morning can improve declining vision

Just three minutes of exposure to deep red light once a week, when delivered in the morning, can significantly improve declining eyesight, finds a pioneering new study by UCL researchers.

Published in Scientific Reports, the study builds on the team's previous work, which showed daily three-minute exposure to longwave deep red light 'switched on' energy producing mitochondria cells in the human retina, helping boost naturally declining vision.

For this latest study, scientists wanted to establish what effect a single three-minute exposure would have, while also using much lower energy levels than their previous studies. Furthermore, building on separate UCL research in flies that found mitochondria display 'shifting workloads' depending on the time of day, the team compared morning exposure to afternoon exposure.

In summary, researchers found there was, on average, a 17% improvement in participants' colour contrast vision when exposed to three minutes of 670 nanometre (long wavelength) deep red light in the morning and the effects of this single exposure lasted for at least a week. However, when the same test was conducted in the afternoon, no improvement was seen.

Scientists say the benefits of deep red light, highlighted by the findings, mark a breakthrough for eye health and should lead to affordable home-based eye therapies, helping the millions of people globally with naturally declining vision.

We demonstrate that one single exposure to long wave deep red light in the morning can significantly improve declining vision, which is a major health and wellbeing issue, affecting millions of people globally.

This simple intervention applied at the population level would significantly impact on quality of life as people age and would likely result in reduced social costs that arise from problems associated with reduced vision."

Glen Jeffery, Lead Author, Professor, UCL Institute of Ophthalmology

Naturally declining vision and mitochondria

In humans around 40 years old, cells in the eye's retina begin to age, and the pace of this ageing is caused, in part, when the cell's mitochondria, whose role is to produce energy (known as ATP) and boost cell function, also start to decline.

Mitochondrial density is greatest in the retina's photoreceptor cells, which have high energy demands. As a result, the retina ages faster than other organs, with a 70% ATP reduction over life, causing a significant decline in photoreceptor function as they lack the energy to perform their normal role.

In studying the effects of deep red light in humans, researchers built on their previous findings in mice, bumblebees and fruit flies, which all found significant improvements in the function of the retina's photoreceptors when their eyes were exposed to 670 nanometre (long wavelength) deep red light.

"Mitochondria have specific sensitivities to long wavelength light influencing their performance: longer wavelengths spanning 650 to 900nm improve mitochondrial performance to increase energy production," said Professor Jeffery.

Morning and afternoon studies

The retina's photoreceptor population is formed of cones, which mediate colour vision, and rods, which adapt vision in low/dim light. This study focused on cones and observed colour contrast sensitivity, along the protan axis (measuring red-green contrast) and the tritan axis (blue-yellow).

All the participants were aged between 34 and 70, had no ocular disease, completed a questionnaire regarding eye health prior to testing, and had normal colour vision (cone function). This was assessed using a 'Chroma Test': identifying coloured letters that had very low contrast and appeared increasingly blurred, a process called colour contrast.

Using a provided LED device all 20 participants (13 female and 7 male) were exposed to three minutes of 670nm deep red light in the morning between 8am and 9am. Their colour vision was then tested again three hours post exposure and 10 of the participants were also tested one week post exposure.

On average there was a 'significant' 17% improvement in colour vision, which lasted a week in tested participants; in some older participants there was a 20% improvement, also lasting a week.

A few months on from the first test (ensuring any positive effects of the deep red light had been 'washed out') six (three female, three male) of the 20 participants, carried out the same test in the afternoon, between 12pm to 1pm. When participants then had their colour vision tested again, it showed zero improvement.

Professor Jeffery said: "Using a simple LED device once a week, recharges the energy system that has declined in the retina cells, rather like re-charging a battery.

"And morning exposure is absolutely key to achieving improvements in declining vision: as we have previously seen in flies, mitochondria have shifting work patterns and do not respond in the same way to light in the afternoon – this study confirms this."

For this study the light energy emitted by the LED torch was just 8mW/cm2, rather than 40mW/cm2, which they had previously used. This has the effect of dimming the light but does not affect the wavelength. While both energy levels are perfectly safe for the human eye, reducing the energy further is an additional benefit.

Home-based affordable eye therapies

With a paucity of affordable deep red-light eye-therapies available, Professor Jeffery has been working for no commercial gain with Planet Lighting UK, a small company in Wales and others, with the aim of producing 670nm infra-red eye ware at an affordable cost, in contrast to some other LED devices designed to improve vision available in the US for over $20,000.

"The technology is simple and very safe; the energy delivered by 670nm long wave light is not that much greater than that found in natural environmental light," Professor Jeffery said.

"Given its simplicity, I am confident an easy-to-use device can be made available at an affordable cost to the general public.

"In the near future, a once a week three-minute exposure to deep red light could be done while making a coffee, or on the commute listening to a podcast, and such a simple addition could transform eye care and vision around the world."

Study limitations

Despite the clarity of the results, researchers say some of the data are "noisy". While positive effects are clear for individuals following 670nm exposure, the magnitude of improvements can vary markedly between those of similar ages. Therefore, some caution is needed in interpretating the data. It is possible that there are other variables between individuals that influence the degree of improvement that the researchers have not identified so far and would require a larger sample size.

This research was funded by the Biotechnology and Biological Sciences Research Council, and Sight Research UK.

To help meet the costs of this research and future research, Professor Glen Jeffery's Lab at the UCL Institute of Ophthalmology receives donations via UCL's Give Now platform.

Source:
Journal reference:

Shinhmar, H., et al. (2021) Weeklong improved colour contrasts sensitivity after single 670nm exposures associated with enhanced mitochondrial function. Scientific Reports. doi.org/10.1038/s41598-021-02311-1.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New CAR T-cell therapy shows promise against aggressive HER2+ breast cancer